Keros Therapeutics Inc

The recent momentum breakout above the consolidation cluster on rising volume confirms demand absorption and supports a bullish medium-term bias in early Stage 1 repair. However, price is currently extended above the rising 9/21 EMAs with no pullback, offering limited execution edge. We defer engagement and await a pullback into the dynamic support zone around the 9 and 21 EMAs for optimal entry.

• ↑Added to Russell Microcap and 2000 Value-Defensive indices, enhancing liquidity.
• ↑Analysts rate Buy, average target $21.83 (+98.6% vs. $10.86 current).
• ↓Q1 loss of $1.21/sh missed forecasts by ~16%, underscoring cash burn.